Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: CCS648 who wrote (1005)	5/6/2025 1:03:56 PM
From: Fitzhughlaw	4 Recommendations Recommended By bobbseytwins2001 erippetoe luckydog88 rodneyh07 Read Replies (2) \| Respond to of 1229

"But if that’s your perception of the intent (obfuscation), why are you an investor here?" My rationale is essentially what you posited - that the science is sufficiently compelling that management's ineptitude and arguably resort to "weasel wording" makes the investment worth the numerous instances of almost throwing up in my mouth. In addition, as this forum's name suggests, we have all been through this, and actually much worse, before. I don't know if you were an IMMU shareholder but if you were, know of what I speak.

To: CCS648 who wrote (1005)	5/6/2025 2:03:33 PM
From: Maturin	2 Recommendations Recommended By bobbseytwins2001 CCS648 Respond to of 1229

The press release reads to me like a CYA from management/PSS to the new investors who placed money at $3 per share, and were likely viewing the papillary disease application as a near term catalyst that would further de-risk their investment. Regardless, count me as another person lowering their cost basis by purchasing shares yesterday and today. I still believe the product has value and with a market cap of under $2bn I like the risk/reward here.